Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
The subcellular localization of organelles, mRNAs and proteins is particularly challenging in neurons. Owing to their extended morphology, with axons in humans exceeding a meter in length, in addition to which they are not renewed but persist for the entire lifespan, it is no surprise that neurons are highly vulnerable to any perturbation of their sophisticated transport machinery. There is emerging evidence that impaired transport is not only causative for a range of motor disorders, but possibly also for Alzheimer's disease (AD) and related neurodegenerative disorders. Support for this hypothesis comes from transgenic animal models. Overexpression of human tau and amyloid precursor protein (APP) in mice and flies models the key hallmark histopathological characteristics of AD, such as somatodendritic accumulation of phosphorylated forms of tau and β‐amyloid (Aβ) peptide‐containing amyloid plaques, as well as axonopathy. The latter has also been demonstrated in mutant mice with altered levels of Alzheimer‐associated genes, such as presenilin (PS). In Aβ‐producing APP transgenic mice, axonopathy was observed before the onset of plaque formation and tau hyperphosphorylation. In human AD brain, an axonopathy was revealed for early but not late Braak stages. The overall picture is that key players in AD, such as tau, APP and PS, perturb axonal transport early on in AD, causing impaired synaptic plasticity and reducing survival rates. It will be challenging to determine the molecular mechanisms of these different axonopathies, as this might assist in the development of new therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 2×
“genes encoding presenilin 1 and 2 (PS1 and PS2), the latter being components of the c-secretase complex (Van Broeckhoven et al. 1992; Sherrington et al. 1995).”
BackgroundVassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 1×
“…generates p3 fragments and the AICD. aSecretase cleavage of APP takes place mainly in the Golgi apparatus and at the plasma membrane (Lammich et al. 1999; Skovronsky et al. 2000), whereas BACE1 is thought to be mostly active in endosomes (Koo and Squazzo 1994; Vassar et al. 1999; Huse et al. 2000).”
BackgroundAssociation of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Caughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650
APP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644 · cited 2×
“…axonal terminals appear to be sufficient to generate Ab (Kawarabayashi et al. 1993; Uchihara et al. 1995; Lazarov et al. 2002; Roher et al. 2002; Kamenetz et al. 2003; Smith et al. 2003; Chen et al. 2004b), axonal transport kinetics of BACE and PS1 are different from those of APP (Lazarov et…”
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 3×
“A role for transport in tauopathies is also evident from an extensive transcriptomic study of P301L mutant tau transgenic mice (Gotz et al. 2001a) and P301L tau-transfected SY5Y neuroblastoma cells (Ferrari et al. 2003; Pennanen and Gotz 2005) using three annotation databases.”
BackgroundMethod
Cited by
Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
Self-citationSynaptic degeneration in Alzheimer's disease
Arendt, T. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0536-x · Cited by 517
“Synaptotrophic function of human wild-type APP and its failure in FAD-mutated APP Disturbances of synaptic function and plasticity have also been observed in transgenic mice overexpressing FAD- mutated APP [32, 54, 62, 65].”
BackgroundTargeting p38 MAPK pathway for the treatment of Alzheimer's disease
Munoz, L., & Ammit, A. J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.11.010 · Cited by 369
Mechanisms of axon degeneration: From development to disease
Saxena, S., & Caroni, P. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.07.007 · Cited by 259
Structural Principles of Tau and the Paired Helical Filaments of Alzheimer's Disease
Mandelkow, E., Von Bergen, M., Biernat, J., & Mandelkow, E. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00053.x · Cited by 243
“So far, a number of different mouse models have been described, resulting in a range of findings that are beyond the scope of this article [for reviews, see (34, 52, 84, 118)].”
Background
Metadata
- Authors
- Götz, J., Ittner, L. M., & Kins, S.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2006-06-19
- Volume
- 98
- Issue
- 4
- Pages
- 993-1006
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2033198098
- Cited by
- 116
- References
- 53
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease? https://app.cochat.ai/papers/10.1111/j.1471-4159.2006.03955.x
- The paper
- Götz, J., Ittner, L. M., & Kins, S. (2006). Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease? Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2006.03955.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.